(PharmaNewsWire.Com, March 01, 2017 ) Gene Therapies Market: A Diverse Range of Technologies with a Promising Long-Term Outlook discusses all gene therapies under the broad criteria of genetic material introduced to the cell for a therapeutic purpose.
Scope of this Gene Therapies Market Research Report:
· clinical or commercial success
Ø Why do gene therapies still occupy only a minimal market share in their respective indications?
Ø What can be learned from the gene therapies market that have already reached the market?
· A number of different viral and non-viral vector types are currently in development for the delivery of gene therapies
Ø What are the relative advantages and disadvantages of each vector type and which hold the most promise?
Ø What proportion of the overall gene therapy R&D pipeline is occupied by each vector type?
· The current pipeline for gene therapies market is diverse in terms of the approaches and vectors covered; 50% are gene silencing therapies, while 31% involve the insertion of a functional gene
Ø In which therapy areas is there the highest level of R&D activity for gene therapies?
Ø At which stage of development does the majority of pipeline gene therapies reside?
Ø What is the proportion of the pipeline occupied by each intervention and vector type overall?
· A number of companies are currently actively developing pipeline gene therapies market, including private, public and institutional enterprises
Ø How do gene therapies fit into the overall portfolios of these companies?
Ø What is the level of involvement in gene therapy research from the top 20 Big Pharma companies?
The pipeline is robust; 906 pipeline gene therapies are currently in development. Most are at an early stage of development, with 76% at the Discovery or Preclinical stage. However, there are currently 23 gene therapy programs in Phase III development and two at the Pre-registration stage. This indicates that although gene therapies market are beginning to reach the market after two decades of research in humans, the majority remain in relatively early development.
Major TOC included in this Gene Therapies Market Report:
Key Reasons to Purchase this Gene Therapies Market Report:
· Understand the current status of the field of therapeutic gene therapies market, and the relative clinical and commercial success of currently marketed products, comprising Glybera, Kynamro, Macugen, Vitravene, Gendicine, Oncorine, and Neovasculgen.
· Assess the pipeline for gene therapies market split by therapy area, vector type and intervention type, and stage of development. Additionally, a granular assessment of the pipeline is provided across the four major therapy areas for gene therapy: oncology, infectious diseases, central nervous system disorders, and genetic disorders.
· Gain a picture of the current competitive landscape, with a detailed breakdown of companies actively involved in the gene therapy pipeline. Understand the level of involvement on the part of big pharma companies, and the extent to which gene therapies market fit into the overall portfolios of companies in this field. Additionally, a highly granular breakdown of companies developing multiple gene therapies is provided.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
